Skip to main content
Top
Published in: Endocrine 3/2014

01-08-2014 | Review

Harmful effects of functional hypercortisolism: a working hypothesis

Authors: Giacomo Tirabassi, Marco Boscaro, Giorgio Arnaldi

Published in: Endocrine | Issue 3/2014

Login to get access

Abstract

Functional hypercortisolism (FH) is caused by conditions able to chronically activate hypothalamic–pituitary–adrenal axis and usually occurs in cases of major depression, anorexia nervosa, bulimia nervosa, alcoholism, diabetes mellitus, simple obesity, polycystic ovary syndrome, obstructive sleep apnea syndrome, panic disorder, generalized anxiety disorder, shift work, and end-stage renal disease. Most of these states belong to pseudo-Cushing disease, a condition which is difficult to distinguish from Cushing’s syndrome and characterized not only by biochemical findings but also by objective ones that can be attributed to hypercortisolism (e.g., striae rubrae, central obesity, skin atrophy, easy bruising, etc.). This hormonal imbalance, although reversible and generally mild, could mediate some systemic complications, mainly but not only of a metabolic/cardiovascular nature, which are present in these states and are largely the same as those present in Cushing’s syndrome. In this review we aim to discuss the evidence suggesting the emerging negative role for FH.
Literature
1.
go back to reference C. Tsigos, G.P. Chousos, Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53, 865–871 (2002)PubMed C. Tsigos, G.P. Chousos, Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53, 865–871 (2002)PubMed
2.
go back to reference G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35, 434–448 (2012)PubMed G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35, 434–448 (2012)PubMed
3.
go back to reference G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)PubMed G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)PubMed
4.
go back to reference G. Arnaldi, G. Tirabassi, R. Papa, G. Furlani, L. Trementino, M. Cardinaletti, E. Faloia, M. Boscaro, Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing’s disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. Eur. J. Endocrinol. 160, 891–898 (2009)PubMed G. Arnaldi, G. Tirabassi, R. Papa, G. Furlani, L. Trementino, M. Cardinaletti, E. Faloia, M. Boscaro, Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing’s disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. Eur. J. Endocrinol. 160, 891–898 (2009)PubMed
5.
go back to reference G. Tirabassi, E. Faloia, R. Papa, G. Furlani, M. Boscaro, G. Arnaldi, Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J. Clin. Endocrinol. Metab. 95, 1115–1122 (2010)PubMed G. Tirabassi, E. Faloia, R. Papa, G. Furlani, M. Boscaro, G. Arnaldi, Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J. Clin. Endocrinol. Metab. 95, 1115–1122 (2010)PubMed
6.
go back to reference G. Tirabassi, R. Papa, E. Faloia, M. Boscaro, G. Arnaldi, Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing’s disease and pseudo-Cushing state: a comparative study. Clin. Endocrinol. (Oxf) 75, 666–672 (2011) G. Tirabassi, R. Papa, E. Faloia, M. Boscaro, G. Arnaldi, Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing’s disease and pseudo-Cushing state: a comparative study. Clin. Endocrinol. (Oxf) 75, 666–672 (2011)
7.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)PubMedCentralPubMed L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)PubMedCentralPubMed
8.
go back to reference S.A. Doi, J. Clark, A.W. Russell, Concordance of the late night salivary cortisol in patients with Cushing’s syndrome and elevated urine-free cortisol. Endocrine 43, 327–333 (2013)PubMed S.A. Doi, J. Clark, A.W. Russell, Concordance of the late night salivary cortisol in patients with Cushing’s syndrome and elevated urine-free cortisol. Endocrine 43, 327–333 (2013)PubMed
9.
go back to reference H. Raff, Update on late-night salivary cortisol for the diagnosis of Cushing’s syndrome: methodological considerations. Endocrine 44, 346–349 (2013)PubMed H. Raff, Update on late-night salivary cortisol for the diagnosis of Cushing’s syndrome: methodological considerations. Endocrine 44, 346–349 (2013)PubMed
10.
go back to reference H. Raff, Salivary cortisol and the diagnosis of Cushing’s syndrome: a coming of age. Endocrine 41, 353–354 (2012)PubMed H. Raff, Salivary cortisol and the diagnosis of Cushing’s syndrome: a coming of age. Endocrine 41, 353–354 (2012)PubMed
11.
go back to reference Z.E. Belaya, A.V. Iljin, G.A. Melnichenko, L.Y. Rozhinskaya, N.V. Dragunova, L.K. Dzeranova, S.A. Butrova, E.A. Troshina, I.I. Dedov, Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. Endocrine 41, 494–500 (2012)PubMed Z.E. Belaya, A.V. Iljin, G.A. Melnichenko, L.Y. Rozhinskaya, N.V. Dragunova, L.K. Dzeranova, S.A. Butrova, E.A. Troshina, I.I. Dedov, Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. Endocrine 41, 494–500 (2012)PubMed
12.
go back to reference C.A. Carrasco, M. García, M. Goycoolea, J. Cerda, J. Bertherat, O. Padilla, D. Meza, N. Wohllk, T. Quiroga, Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing’s syndrome using an automated immunoassay system. Endocrine 41, 487–493 (2012)PubMed C.A. Carrasco, M. García, M. Goycoolea, J. Cerda, J. Bertherat, O. Padilla, D. Meza, N. Wohllk, T. Quiroga, Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing’s syndrome using an automated immunoassay system. Endocrine 41, 487–493 (2012)PubMed
13.
go back to reference M.D. Sullivan, P. O’Connor, P. Feeney, D. Hire, D.L. Simmons, D.W. Raisch, L.J. Fine, K.M. Narayan, M.K. Ali, W.J. Katon, Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care 35, 1708–1715 (2012)PubMedCentralPubMed M.D. Sullivan, P. O’Connor, P. Feeney, D. Hire, D.L. Simmons, D.W. Raisch, L.J. Fine, K.M. Narayan, M.K. Ali, W.J. Katon, Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care 35, 1708–1715 (2012)PubMedCentralPubMed
14.
go back to reference M.S. Player, L.E. Peterson, Anxiety disorders, hypertension, and cardiovascular risk: a review. Int. J. Psychiatry Med. 41, 365–377 (2011)PubMed M.S. Player, L.E. Peterson, Anxiety disorders, hypertension, and cardiovascular risk: a review. Int. J. Psychiatry Med. 41, 365–377 (2011)PubMed
15.
go back to reference H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010)PubMedCentralPubMed H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010)PubMedCentralPubMed
16.
go back to reference A. Pan, N. Keum, O.I. Okereke, Q. Sun, M. Kivimaki, R.R. Rubin, F.B. Hu, Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35, 1171–1180 (2012)PubMedCentralPubMed A. Pan, N. Keum, O.I. Okereke, Q. Sun, M. Kivimaki, R.R. Rubin, F.B. Hu, Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35, 1171–1180 (2012)PubMedCentralPubMed
17.
go back to reference C. Gragnoli, Depression and type 2 diabetes: cortisol pathway implication and investigational needs. J. Cell. Physiol. 227, 2318–2322 (2012)PubMed C. Gragnoli, Depression and type 2 diabetes: cortisol pathway implication and investigational needs. J. Cell. Physiol. 227, 2318–2322 (2012)PubMed
18.
go back to reference D. Kopf, S. Westphal, C.W. Luley, S. Ritter, M. Gilles, B. Weber-Hamann, F. Lederbogen, H. Lehnert, F.A. Henn, I. Heuser, M. Deuschle, Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J. Clin. Psychopharmacol. 24, 527–531 (2004)PubMed D. Kopf, S. Westphal, C.W. Luley, S. Ritter, M. Gilles, B. Weber-Hamann, F. Lederbogen, H. Lehnert, F.A. Henn, I. Heuser, M. Deuschle, Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J. Clin. Psychopharmacol. 24, 527–531 (2004)PubMed
19.
go back to reference Z. Rihmer, M. Arató, Depression and diabetes mellitus. A study of the relationship between serum cortisol and blood sugar levels in patients with endogenous depression. Neuropsychobiology 8, 315–318 (1982)PubMed Z. Rihmer, M. Arató, Depression and diabetes mellitus. A study of the relationship between serum cortisol and blood sugar levels in patients with endogenous depression. Neuropsychobiology 8, 315–318 (1982)PubMed
20.
go back to reference B. Weber-Hamann, F. Hentschel, A. Kniest, M. Deuschle, M. Colla, F. Lederbogen, I. Heuser, Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom. Med. 64, 274–277 (2002)PubMed B. Weber-Hamann, F. Hentschel, A. Kniest, M. Deuschle, M. Colla, F. Lederbogen, I. Heuser, Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom. Med. 64, 274–277 (2002)PubMed
21.
go back to reference G. Veen, E.J. Giltay, R.H. DeRijk, I.M. van Vliet, J. van Pelt, F.G. Zitman, Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism 58, 821–827 (2009)PubMed G. Veen, E.J. Giltay, R.H. DeRijk, I.M. van Vliet, J. van Pelt, F.G. Zitman, Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism 58, 821–827 (2009)PubMed
22.
go back to reference B. Pfohl, M. Rederer, W. Coryell, D. Stangl, Association between post-dexamethasone cortisol level and blood pressure in depressed inpatients. J. Nerv. Ment. Dis. 179, 44–47 (1991)PubMed B. Pfohl, M. Rederer, W. Coryell, D. Stangl, Association between post-dexamethasone cortisol level and blood pressure in depressed inpatients. J. Nerv. Ment. Dis. 179, 44–47 (1991)PubMed
23.
go back to reference N. Vogelzangs, K. Suthers, L. Ferrucci, E.M. Simonsick, A. Ble, M. Schrager, S. Bandinelli, F. Lauretani, S.V. Giannelli, B.W. Penninx, Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 32, 151–159 (2007)PubMedCentralPubMed N. Vogelzangs, K. Suthers, L. Ferrucci, E.M. Simonsick, A. Ble, M. Schrager, S. Bandinelli, F. Lauretani, S.V. Giannelli, B.W. Penninx, Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 32, 151–159 (2007)PubMedCentralPubMed
24.
go back to reference S. Komatsu, M. Yamamoto, K. Arishima, Y. Eguchi, Maternal adrenocortical hormones maintain the early development of pancreatic B cells in the fetal rat. J. Anat. 193, 551–557 (1998)PubMedCentralPubMed S. Komatsu, M. Yamamoto, K. Arishima, Y. Eguchi, Maternal adrenocortical hormones maintain the early development of pancreatic B cells in the fetal rat. J. Anat. 193, 551–557 (1998)PubMedCentralPubMed
25.
go back to reference J.N. Mann, J.H. Thakore, Melancholic depression and abdominal fat distribution: a mini-review. Stress 3, 1–15 (1999)PubMed J.N. Mann, J.H. Thakore, Melancholic depression and abdominal fat distribution: a mini-review. Stress 3, 1–15 (1999)PubMed
26.
go back to reference J.H. Thakore, P.J. Richards, R.H. Reznek, A. Martin, T.G. Dinan, Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol. Psychiatry 41, 1140–1142 (1997)PubMed J.H. Thakore, P.J. Richards, R.H. Reznek, A. Martin, T.G. Dinan, Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol. Psychiatry 41, 1140–1142 (1997)PubMed
27.
go back to reference B.W. Penninx, A.T. Beekman, A. Honig, D.J. Deeg, R.A. Schoevers, J.T. van Eijk, W. van Tilburg, Depression and cardiac mortality: results from a community-based longitudinal study. Arch. Gen. Psychiatry. 58, 221–227 (2001)PubMed B.W. Penninx, A.T. Beekman, A. Honig, D.J. Deeg, R.A. Schoevers, J.T. van Eijk, W. van Tilburg, Depression and cardiac mortality: results from a community-based longitudinal study. Arch. Gen. Psychiatry. 58, 221–227 (2001)PubMed
28.
go back to reference M. Vythilingam, J. Chen, J.D. Bremner, C.M. Mazure, P.K. Maciejewski, J.C. Nelson, Psychotic depression and mortality. Am. J. Psychiatry 160, 574–576 (2003)PubMed M. Vythilingam, J. Chen, J.D. Bremner, C.M. Mazure, P.K. Maciejewski, J.C. Nelson, Psychotic depression and mortality. Am. J. Psychiatry 160, 574–576 (2003)PubMed
29.
go back to reference W. Coryell, J. Fiedorowicz, M. Zimmerman, E. Young, HPA-axis hyperactivity and mortality in psychotic depressive disorder: preliminary findings. Psychoneuroendocrinology 33, 654–658 (2008)PubMedCentralPubMed W. Coryell, J. Fiedorowicz, M. Zimmerman, E. Young, HPA-axis hyperactivity and mortality in psychotic depressive disorder: preliminary findings. Psychoneuroendocrinology 33, 654–658 (2008)PubMedCentralPubMed
30.
go back to reference M.H. Kamphuis, Depression and cardiovascular disease: the role of diet, lifestyle and health (Gildeprint BV, Enschede (the Netherlands), 2006) M.H. Kamphuis, Depression and cardiovascular disease: the role of diet, lifestyle and health (Gildeprint BV, Enschede (the Netherlands), 2006)
31.
go back to reference A.J. Broadley, A. Korszun, E. Abdelaal, V. Moskvina, J. Deanfield, C.J. Jones, M.P. Frenneaux, Metyrapone improves endothelial dysfunction in patients with treated depression. J. Am. Coll. Cardiol. 48, 170–175 (2006)PubMed A.J. Broadley, A. Korszun, E. Abdelaal, V. Moskvina, J. Deanfield, C.J. Jones, M.P. Frenneaux, Metyrapone improves endothelial dysfunction in patients with treated depression. J. Am. Coll. Cardiol. 48, 170–175 (2006)PubMed
32.
go back to reference L.J. Siever, T.W. Uhde, New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol. Psychiatry 19, 131–156 (1984)PubMed L.J. Siever, T.W. Uhde, New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol. Psychiatry 19, 131–156 (1984)PubMed
33.
go back to reference A.J. Mitchell, T.R. Dening, Depression-related cognitive impairment: possibilities for its pharmacological treatment. J. Affect. Disord. 36, 79–87 (1996)PubMed A.J. Mitchell, T.R. Dening, Depression-related cognitive impairment: possibilities for its pharmacological treatment. J. Affect. Disord. 36, 79–87 (1996)PubMed
35.
go back to reference F. Thomson, M. Craighead, Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33, 691–707 (2008)PubMed F. Thomson, M. Craighead, Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33, 691–707 (2008)PubMed
36.
go back to reference M.W. Strachan, R.M. Reynolds, B.M. Frier, R.J. Mitchell, J.F. Price, The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes. Metab. 11, 407–414 (2009)PubMed M.W. Strachan, R.M. Reynolds, B.M. Frier, R.J. Mitchell, J.F. Price, The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes. Metab. 11, 407–414 (2009)PubMed
37.
go back to reference A.M. MacLullich, J.R. Seckl, Diabetes and cognitive decline: are steroids the missing link? Cell Metab. 7, 286–287 (2008)PubMed A.M. MacLullich, J.R. Seckl, Diabetes and cognitive decline: are steroids the missing link? Cell Metab. 7, 286–287 (2008)PubMed
38.
go back to reference P.E. Stokes, The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur. Neuropsychopharmacol. 5(Suppl 1), 77–82 (1995)PubMed P.E. Stokes, The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur. Neuropsychopharmacol. 5(Suppl 1), 77–82 (1995)PubMed
39.
go back to reference D.R. Rubinow, R.M. Post, R. Savard, P.W. Gold, Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen. Psychiatry 41, 279–283 (1984)PubMed D.R. Rubinow, R.M. Post, R. Savard, P.W. Gold, Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen. Psychiatry 41, 279–283 (1984)PubMed
40.
go back to reference J.K. Belanoff, M. Kalehzan, B. Sund, S.K. Fleming Ficek, A.F. Schatzberg, Cortisol activity and cognitive changes in psychotic major depression. Am. J. Psychiatry 158, 1612–1616 (2001)PubMed J.K. Belanoff, M. Kalehzan, B. Sund, S.K. Fleming Ficek, A.F. Schatzberg, Cortisol activity and cognitive changes in psychotic major depression. Am. J. Psychiatry 158, 1612–1616 (2001)PubMed
41.
go back to reference B. Siegel, D. Gurevich, G.F. Oxenkrug, Cognitive impairment and cortisol resistance to dexamethasone suppression in elderly depression. Biol. Psychiatry 25, 229–234 (1989)PubMed B. Siegel, D. Gurevich, G.F. Oxenkrug, Cognitive impairment and cortisol resistance to dexamethasone suppression in elderly depression. Biol. Psychiatry 25, 229–234 (1989)PubMed
42.
go back to reference J. Wauthy, M. Ansseau, R. von Frenckell, C. Mormont, J.J. Legros, Memory disturbances and dexamethasone suppression test in major depression. Biol. Psychiatry 30, 736–738 (1991)PubMed J. Wauthy, M. Ansseau, R. von Frenckell, C. Mormont, J.J. Legros, Memory disturbances and dexamethasone suppression test in major depression. Biol. Psychiatry 30, 736–738 (1991)PubMed
43.
go back to reference G. Winokur, D.W. Black, A. Nasrallah, DST nonsuppressor status: relationship to specific aspects of the depressive syndrome. Biol. Psychiatry 22, 360–368 (1987)PubMed G. Winokur, D.W. Black, A. Nasrallah, DST nonsuppressor status: relationship to specific aspects of the depressive syndrome. Biol. Psychiatry 22, 360–368 (1987)PubMed
44.
go back to reference A. Georgotas, R.E. McCue, O.M. Kim, W.E. Hapworth, B. Reisberg, P.M. Stoll, E. Sinaiko, C. Fanelli, P.E. Stokes, Dexamethasone suppression in dementia, depression, and normal aging. Am. J. Psychiatry 143, 452–456 (1986)PubMed A. Georgotas, R.E. McCue, O.M. Kim, W.E. Hapworth, B. Reisberg, P.M. Stoll, E. Sinaiko, C. Fanelli, P.E. Stokes, Dexamethasone suppression in dementia, depression, and normal aging. Am. J. Psychiatry 143, 452–456 (1986)PubMed
45.
go back to reference D.A. Axelson, P.M. Doraiswamy, W.M. McDonald, O.B. Boyko, L.A. Tupler, L.J. Patterson, C.B. Nemeroff, E.H. Ellinwood Jr, K.R. Krishnan, Hypercortisolemia and hippocampal changes in depression. Psychiatry Res. 47, 163–173 (1993)PubMed D.A. Axelson, P.M. Doraiswamy, W.M. McDonald, O.B. Boyko, L.A. Tupler, L.J. Patterson, C.B. Nemeroff, E.H. Ellinwood Jr, K.R. Krishnan, Hypercortisolemia and hippocampal changes in depression. Psychiatry Res. 47, 163–173 (1993)PubMed
46.
go back to reference G. Cizza, P. Ravn, G.P. Chrousos, P.W. Gold, Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab. 12, 198–203 (2001)PubMed G. Cizza, P. Ravn, G.P. Chrousos, P.W. Gold, Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab. 12, 198–203 (2001)PubMed
47.
go back to reference G. Cizza, S. Primma, G. Csako, Depression as a risk factor for osteoporosis. Trends Endocrinol. Metab. 20, 367–373 (2009)PubMedCentralPubMed G. Cizza, S. Primma, G. Csako, Depression as a risk factor for osteoporosis. Trends Endocrinol. Metab. 20, 367–373 (2009)PubMedCentralPubMed
48.
go back to reference K.M. Yazici, A. Akinci, A. Sütçü, L. Ozçakar, Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. 117, 271–275 (2003)PubMed K.M. Yazici, A. Akinci, A. Sütçü, L. Ozçakar, Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. 117, 271–275 (2003)PubMed
49.
go back to reference J.D. Amsterdam, M.B. Hooper, Bone density measurement in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 267–277 (1998)PubMed J.D. Amsterdam, M.B. Hooper, Bone density measurement in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 267–277 (1998)PubMed
50.
go back to reference D. Michelson, C. Stratakis, L. Hill, J. Reynolds, E. Galliven, G. Chrousos, P. Gold, Bone mineral density in women with depression. N. Engl. J. Med. 335, 1176–1181 (1996)PubMed D. Michelson, C. Stratakis, L. Hill, J. Reynolds, E. Galliven, G. Chrousos, P. Gold, Bone mineral density in women with depression. N. Engl. J. Med. 335, 1176–1181 (1996)PubMed
51.
go back to reference O. Altindag, A. Altindag, M. Asoglu, M. Gunes, N. Soran, Z. Deveci, Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract. 61, 416–420 (2007)PubMed O. Altindag, A. Altindag, M. Asoglu, M. Gunes, N. Soran, Z. Deveci, Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract. 61, 416–420 (2007)PubMed
52.
go back to reference U. Halbreich, N. Rojansky, S. Palter, M. Hreshchyshyn, J. Kreeger, Y. Bakhai, R. Rosan, Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 57, 485–491 (1995)PubMed U. Halbreich, N. Rojansky, S. Palter, M. Hreshchyshyn, J. Kreeger, Y. Bakhai, R. Rosan, Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 57, 485–491 (1995)PubMed
53.
go back to reference F. Eskandari, P.E. Martinez, S. Torvik, T.M. Phillips, E.M. Sternberg, S. Mistry, D. Ronsaville, R. Wesley, C. Toomey, N.G. Sebring, J.C. Reynolds, M.R. Blackman, K.A. Calis, P.W. Gold, G. Cizza, Premenopausal, Osteoporosis Women, Alendronate, Depression (POWER) Study Group, Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167, 2329–2336 (2007)PubMed F. Eskandari, P.E. Martinez, S. Torvik, T.M. Phillips, E.M. Sternberg, S. Mistry, D. Ronsaville, R. Wesley, C. Toomey, N.G. Sebring, J.C. Reynolds, M.R. Blackman, K.A. Calis, P.W. Gold, G. Cizza, Premenopausal, Osteoporosis Women, Alendronate, Depression (POWER) Study Group, Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167, 2329–2336 (2007)PubMed
54.
go back to reference M.A. Tichomirowa, M.E. Keck, H.J. Schneider, M. Paez-Pereda, U. Renner, F. Holsboer, G.K. Stalla, Endocrine disturbances in depression. J. Endocrinol. Invest. 28, 89–99 (2005)PubMed M.A. Tichomirowa, M.E. Keck, H.J. Schneider, M. Paez-Pereda, U. Renner, F. Holsboer, G.K. Stalla, Endocrine disturbances in depression. J. Endocrinol. Invest. 28, 89–99 (2005)PubMed
55.
go back to reference W. Pitchot, J. Reggers, E. Pinto, M. Hansenne, M. Ansseau, Catecholamine and HPA axis dysfunction in depression: relationship with suicidal behavior. Neuropsychobiology 47, 152–157 (2003)PubMed W. Pitchot, J. Reggers, E. Pinto, M. Hansenne, M. Ansseau, Catecholamine and HPA axis dysfunction in depression: relationship with suicidal behavior. Neuropsychobiology 47, 152–157 (2003)PubMed
56.
go back to reference E. Syvälahti, Dexamethasone suppression test and the levels of serum growth hormone, plasma vasopressin and plasma homovanillic acid in depressed in- and out-patients. Acta Psychiatr. Scand. 71, 105–110 (1985)PubMed E. Syvälahti, Dexamethasone suppression test and the levels of serum growth hormone, plasma vasopressin and plasma homovanillic acid in depressed in- and out-patients. Acta Psychiatr. Scand. 71, 105–110 (1985)PubMed
57.
go back to reference F. Contreras, J.M. Menchon, M. Urretavizcaya, M.A. Navarro, J. Vallejo, G. Parker, Hormonal differences between psychotic and non-psychotic melancholic depression. J. Affect. Disord. 100, 65–73 (2007)PubMed F. Contreras, J.M. Menchon, M. Urretavizcaya, M.A. Navarro, J. Vallejo, G. Parker, Hormonal differences between psychotic and non-psychotic melancholic depression. J. Affect. Disord. 100, 65–73 (2007)PubMed
58.
go back to reference K. O’Flynn, T.G. Dinan, Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result. Am. J. Psychiatry 150, 1728–1730 (1993)PubMed K. O’Flynn, T.G. Dinan, Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result. Am. J. Psychiatry 150, 1728–1730 (1993)PubMed
59.
go back to reference R.J. Dolan, S.P. Calloway, The human growth hormone response to clonidine: relationship to clinical and neuroendocrine profile in depression. Am. J. Psychiatry 143, 772–774 (1986)PubMed R.J. Dolan, S.P. Calloway, The human growth hormone response to clonidine: relationship to clinical and neuroendocrine profile in depression. Am. J. Psychiatry 143, 772–774 (1986)PubMed
60.
go back to reference F. Duval, M.C. Mokrani, J.P. Macher, Reply to letter to the editor. Psychoneuroendocrinology 32, 211–212 (2007) F. Duval, M.C. Mokrani, J.P. Macher, Reply to letter to the editor. Psychoneuroendocrinology 32, 211–212 (2007)
61.
go back to reference S.D. Targum, A.C. Sullivan, S.M. Byrnes, Neuroendocrine interrelationships in major depressive disorder. Am. J. Psychiatry 139, 282–286 (1982)PubMed S.D. Targum, A.C. Sullivan, S.M. Byrnes, Neuroendocrine interrelationships in major depressive disorder. Am. J. Psychiatry 139, 282–286 (1982)PubMed
62.
go back to reference C. Kirkegaard, B.J. Carroll, Dissociation of TSH adrenocortical disturbances in endogenous depression. Psychiatry Res. 3, 253–264 (1980)PubMed C. Kirkegaard, B.J. Carroll, Dissociation of TSH adrenocortical disturbances in endogenous depression. Psychiatry Res. 3, 253–264 (1980)PubMed
64.
go back to reference M. Maes, M. Vandewoude, L. Maes, C. Schotte, P. Cosyns, A revised interpretation of the TRH test results in female depressed patients. Part I: TSH responses. Effects of severity of illness, thyroid hormones, monoamines, age, sex hormonal, corticosteroid and nutritional state. J. Affect. Disord. 16, 203–213 (1989)PubMed M. Maes, M. Vandewoude, L. Maes, C. Schotte, P. Cosyns, A revised interpretation of the TRH test results in female depressed patients. Part I: TSH responses. Effects of severity of illness, thyroid hormones, monoamines, age, sex hormonal, corticosteroid and nutritional state. J. Affect. Disord. 16, 203–213 (1989)PubMed
65.
go back to reference H. Agren, L. Wide, TRH tests with analyses of TSH, prolactin, and GH responses in subtypes of patients with major depressive disorders. Acta Psychiatr. Scand. 73, 549–558 (1986)PubMed H. Agren, L. Wide, TRH tests with analyses of TSH, prolactin, and GH responses in subtypes of patients with major depressive disorders. Acta Psychiatr. Scand. 73, 549–558 (1986)PubMed
66.
go back to reference L. Bartalena, G.F. Placidi, E. Martino, M. Falcone, L. Pellegrini, L. Dell’Osso, A. Pacchiarotti, A. Pinchera, Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J. Clin. Endocrinol. Metab. 71, 650–655 (1990)PubMed L. Bartalena, G.F. Placidi, E. Martino, M. Falcone, L. Pellegrini, L. Dell’Osso, A. Pacchiarotti, A. Pinchera, Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J. Clin. Endocrinol. Metab. 71, 650–655 (1990)PubMed
67.
go back to reference A.J. Rush, D.E. Giles, M.A. Schlesser, P.J. Orsulak, J.E. Weissenburger, C.L. Fulton, C.J. Fairchild, H.P. Roffwarg, Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol. Psychiatry 41, 915–928 (1997)PubMed A.J. Rush, D.E. Giles, M.A. Schlesser, P.J. Orsulak, J.E. Weissenburger, C.L. Fulton, C.J. Fairchild, H.P. Roffwarg, Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol. Psychiatry 41, 915–928 (1997)PubMed
68.
go back to reference E.A. Young, A. Korszun, The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol. Metab. Clin. North Am. 31, 63–78 (2002)PubMed E.A. Young, A. Korszun, The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol. Metab. Clin. North Am. 31, 63–78 (2002)PubMed
69.
go back to reference S.N. Seidman, S.P. Roose, The relationship between depression and erectile dysfunction. Curr. Psychiatry Rep. 2, 201–205 (2000)PubMed S.N. Seidman, S.P. Roose, The relationship between depression and erectile dysfunction. Curr. Psychiatry Rep. 2, 201–205 (2000)PubMed
70.
go back to reference U. Schweiger, M. Deuschle, B. Weber, A. Körner, C.H. Lammers, J. Schmider, U. Gotthardt, I. Heuser, Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom. Med. 61, 292–296 (1999)PubMed U. Schweiger, M. Deuschle, B. Weber, A. Körner, C.H. Lammers, J. Schmider, U. Gotthardt, I. Heuser, Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom. Med. 61, 292–296 (1999)PubMed
71.
go back to reference A. Steiger, U. von Bardeleben, K. Wiedemann, F. Holsboer, Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J. Psychiatr. Res. 25, 169–177 (1991)PubMed A. Steiger, U. von Bardeleben, K. Wiedemann, F. Holsboer, Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J. Psychiatr. Res. 25, 169–177 (1991)PubMed
72.
go back to reference R.T. Rubin, R.E. Poland, I.M. Lesser, Neuroendocrine aspects of primary endogenous depression VIII. Pituitary-gonadal axis activity in male patients and matched control subjects. Psychoneuroendocrinology 14, 217–229 (1989)PubMed R.T. Rubin, R.E. Poland, I.M. Lesser, Neuroendocrine aspects of primary endogenous depression VIII. Pituitary-gonadal axis activity in male patients and matched control subjects. Psychoneuroendocrinology 14, 217–229 (1989)PubMed
73.
go back to reference D.F. Swaab, A.M. Bao, P.J. Lucassen, The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 4, 141–194 (2005)PubMed D.F. Swaab, A.M. Bao, P.J. Lucassen, The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 4, 141–194 (2005)PubMed
74.
go back to reference F. Petraglia, S. Sutton, W. Vale, P. Plotsky, Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 120, 1083–1088 (1987)PubMed F. Petraglia, S. Sutton, W. Vale, P. Plotsky, Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 120, 1083–1088 (1987)PubMed
75.
go back to reference E.L. Perez, J. Blouin, A. Blouin, The dexamethasone suppression test in bulimia: nonsuppression associated with depression and suboptimal weight. J. Clin. Psychiatry 49, 94–96 (1988)PubMed E.L. Perez, J. Blouin, A. Blouin, The dexamethasone suppression test in bulimia: nonsuppression associated with depression and suboptimal weight. J. Clin. Psychiatry 49, 94–96 (1988)PubMed
76.
go back to reference N. Piran, S. Kennedy, P.E. Garfinkel, M. Owens, Affective disturbance in eating disorders. J. Nerv. Ment. Dis. 173, 395–400 (1985)PubMed N. Piran, S. Kennedy, P.E. Garfinkel, M. Owens, Affective disturbance in eating disorders. J. Nerv. Ment. Dis. 173, 395–400 (1985)PubMed
77.
go back to reference E.A. Lawson, D. Donoho, K.K. Miller, M. Misra, E. Meenaghan, J. Lydecker, T. Wexler, D.B. Herzog, A. Klibanski, Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 4710–4716 (2009)PubMedCentralPubMed E.A. Lawson, D. Donoho, K.K. Miller, M. Misra, E. Meenaghan, J. Lydecker, T. Wexler, D.B. Herzog, A. Klibanski, Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 4710–4716 (2009)PubMedCentralPubMed
78.
go back to reference K.R. Bruce, H. Steiger, M. Israël, P. Groleau, N.M. Ng Ying Kin, A.S. Ouellette, L. Sycz, G. Badawi, Cortisol responses on the dexamethasone suppression test among women with Bulimia-spectrum eating disorders: associations with clinical symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 241–246 (2012)PubMed K.R. Bruce, H. Steiger, M. Israël, P. Groleau, N.M. Ng Ying Kin, A.S. Ouellette, L. Sycz, G. Badawi, Cortisol responses on the dexamethasone suppression test among women with Bulimia-spectrum eating disorders: associations with clinical symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 241–246 (2012)PubMed
79.
go back to reference R.G. Laessle, M. Fischer, M.M. Fichter, K.M. Pirke, J.C. Krieg, Cortisol levels and vigilance in eating disorder patients. Psychoneuroendocrinology 17, 475–484 (1992)PubMed R.G. Laessle, M. Fischer, M.M. Fichter, K.M. Pirke, J.C. Krieg, Cortisol levels and vigilance in eating disorder patients. Psychoneuroendocrinology 17, 475–484 (1992)PubMed
80.
go back to reference C. Lauer, W. Schreiber, M. Berger, K.M. Pirke, F. Holsboer, J.C. Krieg, The effect of neuroendocrine secretion on brain morphology and EEG sleep in patients with eating disorders. Eur. Arch. Psychiatry Neurol. Sci. 238, 208–212 (1989)PubMed C. Lauer, W. Schreiber, M. Berger, K.M. Pirke, F. Holsboer, J.C. Krieg, The effect of neuroendocrine secretion on brain morphology and EEG sleep in patients with eating disorders. Eur. Arch. Psychiatry Neurol. Sci. 238, 208–212 (1989)PubMed
81.
go back to reference D.K. Katzman, E.K. Lambe, D.J. Mikulis, J.N. Ridgley, D.S. Goldbloom, R.B. Zipursky, Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J. Pediatr. 129, 794–803 (1996)PubMed D.K. Katzman, E.K. Lambe, D.J. Mikulis, J.N. Ridgley, D.S. Goldbloom, R.B. Zipursky, Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J. Pediatr. 129, 794–803 (1996)PubMed
82.
go back to reference J. Castro-Fornieles, N. Bargalló, L. Lázaro, S. Andrés, C. Falcon, M.T. Plana, C. Junqué, A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J. Psychiatr. Res. 43, 331–340 (2009)PubMed J. Castro-Fornieles, N. Bargalló, L. Lázaro, S. Andrés, C. Falcon, M.T. Plana, C. Junqué, A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J. Psychiatr. Res. 43, 331–340 (2009)PubMed
83.
go back to reference G.D. Giordano, P. Renzetti, R.C. Parodi, L. Foppiani, F. Zandrino, G. Giordano, F. Sardanelli, Volume measurement with magnetic resonance imaging of hippocampus-amygdala formation in patients with anorexia nervosa. J. Endocrinol. Invest. 24, 510–514 (2001)PubMed G.D. Giordano, P. Renzetti, R.C. Parodi, L. Foppiani, F. Zandrino, G. Giordano, F. Sardanelli, Volume measurement with magnetic resonance imaging of hippocampus-amygdala formation in patients with anorexia nervosa. J. Endocrinol. Invest. 24, 510–514 (2001)PubMed
84.
go back to reference J.A. Seed, R.A. Dixon, S.E. McCluskey, A.H. Young, Basal activity of the hypothalamic-pituitary-adrenal axis and cognitive function in anorexia nervosa. Eur. Arch. Psychiatry Clin. Neurosci. 250, 11–15 (2000)PubMed J.A. Seed, R.A. Dixon, S.E. McCluskey, A.H. Young, Basal activity of the hypothalamic-pituitary-adrenal axis and cognitive function in anorexia nervosa. Eur. Arch. Psychiatry Clin. Neurosci. 250, 11–15 (2000)PubMed
85.
go back to reference J. Jolles, Neuropeptides and cognitive disorders. Prog. Brain Res. 65, 177–192 (1986)PubMed J. Jolles, Neuropeptides and cognitive disorders. Prog. Brain Res. 65, 177–192 (1986)PubMed
86.
go back to reference E.A. Lawson, A. Klibanski, Endocrine abnormalities in anorexia nervosa. Nat. Clin. Pract. Endocrinol. Metab. 4, 407–414 (2008)PubMed E.A. Lawson, A. Klibanski, Endocrine abnormalities in anorexia nervosa. Nat. Clin. Pract. Endocrinol. Metab. 4, 407–414 (2008)PubMed
87.
go back to reference J.R. Newton, C.P. Freeman, W.J. Hannan, S. Cowen, Osteoporosis and normal weight bulimia nervosa–which patients are at risk? J. Psychosom. Res. 37, 239–247 (1993)PubMed J.R. Newton, C.P. Freeman, W.J. Hannan, S. Cowen, Osteoporosis and normal weight bulimia nervosa–which patients are at risk? J. Psychosom. Res. 37, 239–247 (1993)PubMed
88.
go back to reference S. Zipfel, M.J. Seibel, B. Löwe, P.J. Beumont, C. Kasperk, W. Herzog, Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. J. Clin. Endocrinol. Metab. 86, 5227–5233 (2001)PubMed S. Zipfel, M.J. Seibel, B. Löwe, P.J. Beumont, C. Kasperk, W. Herzog, Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. J. Clin. Endocrinol. Metab. 86, 5227–5233 (2001)PubMed
89.
go back to reference F. Jacoangeli, A. Zoli, A. Taranto, F. Staar Mezzasalma, C. Ficoneri, S. Pierangeli, G. Menzinger, M.R. Bollea, Osteoporosis and anorexia nervosa: relative role of endocrine alterations and malnutrition. Eat. Weight. Disord. 7, 190–195 (2002)PubMed F. Jacoangeli, A. Zoli, A. Taranto, F. Staar Mezzasalma, C. Ficoneri, S. Pierangeli, G. Menzinger, M.R. Bollea, Osteoporosis and anorexia nervosa: relative role of endocrine alterations and malnutrition. Eat. Weight. Disord. 7, 190–195 (2002)PubMed
90.
go back to reference B.M. Biller, V. Saxe, D.B. Herzog, D.I. Rosenthal, S. Holzman, A. Klibanski, Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J. Clin. Endocrinol. Metab. 68, 548–554 (1989)PubMed B.M. Biller, V. Saxe, D.B. Herzog, D.I. Rosenthal, S. Holzman, A. Klibanski, Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J. Clin. Endocrinol. Metab. 68, 548–554 (1989)PubMed
91.
go back to reference K.A. Carmichael, D.H. Carmichael, Bone metabolism and osteopenia in eating disorders. Medicine (Baltimore) 74, 254–267 (1995) K.A. Carmichael, D.H. Carmichael, Bone metabolism and osteopenia in eating disorders. Medicine (Baltimore) 74, 254–267 (1995)
92.
go back to reference M. Misra, R. Prabhakaran, K.K. Miller, M.A. Goldstein, D. Mickley, L. Clauss, P. Lockhart, J. Cord, D.B. Herzog, D.K. Katzman, A. Klibanski, Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J. Clin. Endocrinol. Metab. 93, 1292–1297 (2008)PubMedCentralPubMed M. Misra, R. Prabhakaran, K.K. Miller, M.A. Goldstein, D. Mickley, L. Clauss, P. Lockhart, J. Cord, D.B. Herzog, D.K. Katzman, A. Klibanski, Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J. Clin. Endocrinol. Metab. 93, 1292–1297 (2008)PubMedCentralPubMed
93.
go back to reference S. Naessén, K. Carlström, R. Glant, H. Jacobsson, A.L. Hirschberg, Bone mineral density in bulimic women-influence of endocrine factors and previous anorexia. Eur. J. Endocrinol. 155, 245–251 (2006)PubMed S. Naessén, K. Carlström, R. Glant, H. Jacobsson, A.L. Hirschberg, Bone mineral density in bulimic women-influence of endocrine factors and previous anorexia. Eur. J. Endocrinol. 155, 245–251 (2006)PubMed
94.
go back to reference ESHRE Capri Workshop Group, Nutrition and reproduction in women. Hum. Reprod. Update 12, 193–207 (2006) ESHRE Capri Workshop Group, Nutrition and reproduction in women. Hum. Reprod. Update 12, 193–207 (2006)
95.
go back to reference U. Schweiger, K.M. Pirke, R.G. Laessle, M.M. Fichter, Gonadotropin secretion in bulimia nervosa. J. Clin. Endocrinol. Metab. 74, 1122–1127 (1992)PubMed U. Schweiger, K.M. Pirke, R.G. Laessle, M.M. Fichter, Gonadotropin secretion in bulimia nervosa. J. Clin. Endocrinol. Metab. 74, 1122–1127 (1992)PubMed
96.
go back to reference M. Misra, K.K. Miller, J. Bjornson, A. Hackman, A. Aggarwal, J. Chung, M. Ott, D.B. Herzog, M.L. Johnson, A. Klibanski, Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88, 5615–5623 (2003)PubMed M. Misra, K.K. Miller, J. Bjornson, A. Hackman, A. Aggarwal, J. Chung, M. Ott, D.B. Herzog, M.L. Johnson, A. Klibanski, Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88, 5615–5623 (2003)PubMed
97.
go back to reference R.K. Støving, J.D. Veldhuis, A. Flyvbjerg, J. Vinten, J. Hangaard, O.G. Koldkjaer, J. Kristiansen, C. Hagen, Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J. Clin. Endocrinol. Metab. 84, 2056–2063 (1999)PubMed R.K. Støving, J.D. Veldhuis, A. Flyvbjerg, J. Vinten, J. Hangaard, O.G. Koldkjaer, J. Kristiansen, C. Hagen, Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J. Clin. Endocrinol. Metab. 84, 2056–2063 (1999)PubMed
98.
go back to reference C. Bannai, N. Kuzuya, Y. Koide, T. Fujita, M. Itakura, K. Kawai, K. Yamashita, Assessment of the relationship between serum thyroid hormone levels and peripheral metabolism in patients with anorexia nervosa. Endocrinol. Jpn. 35, 455–462 (1988)PubMed C. Bannai, N. Kuzuya, Y. Koide, T. Fujita, M. Itakura, K. Kawai, K. Yamashita, Assessment of the relationship between serum thyroid hormone levels and peripheral metabolism in patients with anorexia nervosa. Endocrinol. Jpn. 35, 455–462 (1988)PubMed
99.
go back to reference H. Tamai, N. Kobayashi, S. Fukata, Y. Hirota, S. Matsubayashi, T. Nakagawa, M.C. Okimura, R.M. Walter Jr, L.F. Kumagai, Paradoxical responses of plasma cortisol, adrenocorticotropic hormone and growth hormone to thyrotropin-releasing hormone and luteinizing-hormone-releasing hormone in anorexia nervosa patients. Psychother. Psychosom. 46, 147–151 (1986)PubMed H. Tamai, N. Kobayashi, S. Fukata, Y. Hirota, S. Matsubayashi, T. Nakagawa, M.C. Okimura, R.M. Walter Jr, L.F. Kumagai, Paradoxical responses of plasma cortisol, adrenocorticotropic hormone and growth hormone to thyrotropin-releasing hormone and luteinizing-hormone-releasing hormone in anorexia nervosa patients. Psychother. Psychosom. 46, 147–151 (1986)PubMed
100.
go back to reference S. Grinspoon, L. Thomas, K. Miller, S. Pitts, D. Herzog, A. Klibanski, Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 73, 865–869 (2001)PubMed S. Grinspoon, L. Thomas, K. Miller, S. Pitts, D. Herzog, A. Klibanski, Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 73, 865–869 (2001)PubMed
101.
go back to reference L. Mayer, B.T. Walsh, R.N. Pierson Jr, S.B. Heymsfield, D. Gallagher, J. Wang, M.K. Parides, R.L. Leibel, M.P. Warren, E. Killory, D. Glasofer, Body fat redistribution after weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 81, 1286–1291 (2005)PubMed L. Mayer, B.T. Walsh, R.N. Pierson Jr, S.B. Heymsfield, D. Gallagher, J. Wang, M.K. Parides, R.L. Leibel, M.P. Warren, E. Killory, D. Glasofer, Body fat redistribution after weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 81, 1286–1291 (2005)PubMed
102.
go back to reference J. Balldin, U. Berggren, K. Bokström, G. Lindstedt, J. Sjöberg, C. Wendestam, Dexamethasone suppression test in alcohol withdrawal: relationship to depression and liver function. Drug Alcohol Depend. 30, 175–179 (1992)PubMed J. Balldin, U. Berggren, K. Bokström, G. Lindstedt, J. Sjöberg, C. Wendestam, Dexamethasone suppression test in alcohol withdrawal: relationship to depression and liver function. Drug Alcohol Depend. 30, 175–179 (1992)PubMed
103.
go back to reference M.T. Abou-Saleh, J. Merry, A. Coppen, Dexamethasone suppression test in alcoholism. Acta Psychiatr. Scand. 69, 112–116 (1984)PubMed M.T. Abou-Saleh, J. Merry, A. Coppen, Dexamethasone suppression test in alcoholism. Acta Psychiatr. Scand. 69, 112–116 (1984)PubMed
104.
go back to reference S.K. Majumdar, G.K. Shaw, P.K. Bridges, Relationship between plasma cortisol concentrations and depression in chronic alcoholic patients. Drug Alcohol Depend 14, 45–49 (1984)PubMed S.K. Majumdar, G.K. Shaw, P.K. Bridges, Relationship between plasma cortisol concentrations and depression in chronic alcoholic patients. Drug Alcohol Depend 14, 45–49 (1984)PubMed
105.
go back to reference A. Heinz, H. Weingartner, D. George, D. Hommer, O.M. Wolkowitz, M. Linnoila, Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Res. 89, 97–106 (1999)PubMed A. Heinz, H. Weingartner, D. George, D. Hommer, O.M. Wolkowitz, M. Linnoila, Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Res. 89, 97–106 (1999)PubMed
106.
go back to reference N. Müller, M. Hoehe, H.E. Klein, G. Nieberle, H.P. Kapfhammer, F. May, O.A. Müller, M. Fichter, Endocrinological studies in alcoholics during withdrawal and after abstinence. Psychoneuroendocrinology 14, 113–123 (1989)PubMed N. Müller, M. Hoehe, H.E. Klein, G. Nieberle, H.P. Kapfhammer, F. May, O.A. Müller, M. Fichter, Endocrinological studies in alcoholics during withdrawal and after abstinence. Psychoneuroendocrinology 14, 113–123 (1989)PubMed
107.
go back to reference M. Huntgeburth, H. Ten Freyhaus, S. Rosenkranz, Alcohol consumption and hypertension. Curr. Hypertens. Rep. 7, 180–185 (2005)PubMed M. Huntgeburth, H. Ten Freyhaus, S. Rosenkranz, Alcohol consumption and hypertension. Curr. Hypertens. Rep. 7, 180–185 (2005)PubMed
108.
go back to reference J.F. Potter, L.T. Bannan, J.B. Saunders, M.C. Ingram, D.G. Beevers, Blood pressure and pressor mechanisms during alcohol withdrawal. J. Hypertens. Suppl. 1, 97–99 (1983)PubMed J.F. Potter, L.T. Bannan, J.B. Saunders, M.C. Ingram, D.G. Beevers, Blood pressure and pressor mechanisms during alcohol withdrawal. J. Hypertens. Suppl. 1, 97–99 (1983)PubMed
109.
go back to reference L.T. Bannan, J.F. Potter, D.G. Beevers, J.B. Saunders, J.R. Walters, M.C. Ingram, Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin. Sci. (Lond) 66, 659–663 (1984) L.T. Bannan, J.F. Potter, D.G. Beevers, J.B. Saunders, J.R. Walters, M.C. Ingram, Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin. Sci. (Lond) 66, 659–663 (1984)
110.
go back to reference D.B. Maurel, N. Boisseau, C.L. Benhamou, C. Jaffre, Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 23, 1–16 (2012)PubMed D.B. Maurel, N. Boisseau, C.L. Benhamou, C. Jaffre, Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 23, 1–16 (2012)PubMed
111.
go back to reference R.M. Couch, Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus. Acta Endocrinol. (Copenh.) 127, 115–117 (1992) R.M. Couch, Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus. Acta Endocrinol. (Copenh.) 127, 115–117 (1992)
112.
go back to reference T.B. Kaye, R.A. Rubin, A.B. Goldfine, K. Rajamani, B.T. Kinsley, U.M. Vischer, D.C. Simonson, Effect of glycemic control on the overnight dexamethasone suppression test in patients with diabetes mellitus. J. Clin. Endocrinol. Metab. 74, 640–644 (1992)PubMed T.B. Kaye, R.A. Rubin, A.B. Goldfine, K. Rajamani, B.T. Kinsley, U.M. Vischer, D.C. Simonson, Effect of glycemic control on the overnight dexamethasone suppression test in patients with diabetes mellitus. J. Clin. Endocrinol. Metab. 74, 640–644 (1992)PubMed
113.
go back to reference J.I. Hudson, M.S. Hudson, A.J. Rothschild, L. Vignati, A.F. Schatzberg, J.C. Melby, Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch. Gen. Psychiatry 41, 1086–1089 (1984)PubMed J.I. Hudson, M.S. Hudson, A.J. Rothschild, L. Vignati, A.F. Schatzberg, J.C. Melby, Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch. Gen. Psychiatry 41, 1086–1089 (1984)PubMed
114.
go back to reference A.A. Mosbah, N.A. Abd-Ellatif, E.I. Sorour, Influence of serum cortisol levels on glycemic control in children with type 1 diabetes. J. Egypt Soc. Parasitol. 41, 777–784 (2011)PubMed A.A. Mosbah, N.A. Abd-Ellatif, E.I. Sorour, Influence of serum cortisol levels on glycemic control in children with type 1 diabetes. J. Egypt Soc. Parasitol. 41, 777–784 (2011)PubMed
115.
go back to reference G. Valsamakis, A. Anwar, J.W. Tomlinson, C.H. Shackleton, P.G. McTernan, R. Chetty, P.J. Wood, A.K. Banerjee, G. Holder, A.H. Barnett, P.M. Stewart, S. Kumar, 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89, 4755–4761 (2004)PubMed G. Valsamakis, A. Anwar, J.W. Tomlinson, C.H. Shackleton, P.G. McTernan, R. Chetty, P.J. Wood, A.K. Banerjee, G. Holder, A.H. Barnett, P.M. Stewart, S. Kumar, 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89, 4755–4761 (2004)PubMed
116.
go back to reference S.B. Abraham, D. Rubino, N. Sinaii, S. Ramsey, L.K. Nieman, Cortisol, obesity and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity 21, 105–117 (2013) S.B. Abraham, D. Rubino, N. Sinaii, S. Ramsey, L.K. Nieman, Cortisol, obesity and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity 21, 105–117 (2013)
117.
go back to reference K.M. Oltmanns, B. Dodt, B. Schultes, H.H. Raspe, U. Schweiger, J. Born, H.L. Fehm, A. Peters, Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur. J. Endocrinol. 154, 325–331 (2006)PubMed K.M. Oltmanns, B. Dodt, B. Schultes, H.H. Raspe, U. Schweiger, J. Born, H.L. Fehm, A. Peters, Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur. J. Endocrinol. 154, 325–331 (2006)PubMed
118.
go back to reference E. Rask, B.R. Walker, S. Söderberg, D.E. Livingstone, M. Eliasson, O. Johnson, R. Andrew, T. Olsson, Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87, 3330–3336 (2002)PubMed E. Rask, B.R. Walker, S. Söderberg, D.E. Livingstone, M. Eliasson, O. Johnson, R. Andrew, T. Olsson, Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87, 3330–3336 (2002)PubMed
119.
go back to reference R.S. Lindsay, D.J. Wake, S. Nair, J. Bunt, D.E. Livingstone, P.A. Permana, P.A. Tataranni, B.R. Walker, Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88, 2738–2744 (2003)PubMed R.S. Lindsay, D.J. Wake, S. Nair, J. Bunt, D.E. Livingstone, P.A. Permana, P.A. Tataranni, B.R. Walker, Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88, 2738–2744 (2003)PubMed
120.
go back to reference L.L. Gathercole, P.M. Stewart, Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J. Steroid Biochem. Mol. Biol. 122, 21–27 (2010)PubMed L.L. Gathercole, P.M. Stewart, Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J. Steroid Biochem. Mol. Biol. 122, 21–27 (2010)PubMed
121.
go back to reference R.C. Andrews, O. Rooyackers, B.R. Walker, Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 285–291 (2003)PubMed R.C. Andrews, O. Rooyackers, B.R. Walker, Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 285–291 (2003)PubMed
122.
go back to reference M. Hawkins, D. Hunter, P. Kishore, S. Schwartz, M. Hompesch, G. Hollis, R. Levy, B. Williams, R. Huber, INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes 57(Suppl 1), A99–A100 (2008). (Abstract 1) M. Hawkins, D. Hunter, P. Kishore, S. Schwartz, M. Hompesch, G. Hollis, R. Levy, B. Williams, R. Huber, INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes 57(Suppl 1), A99–A100 (2008). (Abstract 1)
123.
go back to reference R.M. Reynolds, J. Labad, M.W. Strachan, A. Braun, F.G. Fowkes, A.J. Lee, B.M. Frier, J.R. Seckl, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study (ET2DS) Investigators, Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study. J. Clin. Endocrinol. Metab. 95, 1602–1608 (2010)PubMedCentralPubMed R.M. Reynolds, J. Labad, M.W. Strachan, A. Braun, F.G. Fowkes, A.J. Lee, B.M. Frier, J.R. Seckl, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study (ET2DS) Investigators, Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study. J. Clin. Endocrinol. Metab. 95, 1602–1608 (2010)PubMedCentralPubMed
124.
go back to reference M. Peppa-Patrikiou, M. Scordili, A. Antoniou, M. Giannaki, M. Dracopoulou, C. Dacou-Voutetakis, Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care 21, 1004–1007 (1998)PubMed M. Peppa-Patrikiou, M. Scordili, A. Antoniou, M. Giannaki, M. Dracopoulou, C. Dacou-Voutetakis, Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care 21, 1004–1007 (1998)PubMed
125.
go back to reference C. Dacou-Voutetakis, M. Peppa-Patrikiou, M. Dracopoulou, Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. J. Pediatr. Endocrinol. Metab. 11, 437–445 (1998)PubMed C. Dacou-Voutetakis, M. Peppa-Patrikiou, M. Dracopoulou, Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. J. Pediatr. Endocrinol. Metab. 11, 437–445 (1998)PubMed
126.
go back to reference I. Chiodini, G. Adda, A. Scillitani, F. Coletti, V. Morelli, S. Di Lembo, P. Epaminonda, B. Masserini, P. Beck-Peccoz, E. Orsi, B. Ambrosi, M. Arosio, Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30, 83–88 (2007)PubMed I. Chiodini, G. Adda, A. Scillitani, F. Coletti, V. Morelli, S. Di Lembo, P. Epaminonda, B. Masserini, P. Beck-Peccoz, E. Orsi, B. Ambrosi, M. Arosio, Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30, 83–88 (2007)PubMed
127.
go back to reference A.M. Stranahan, T.V. Arumugam, R.G. Cutler, K. Lee, J.M. Egan, M.P. Mattson, Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11, 309–317 (2008)PubMedCentralPubMed A.M. Stranahan, T.V. Arumugam, R.G. Cutler, K. Lee, J.M. Egan, M.P. Mattson, Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11, 309–317 (2008)PubMedCentralPubMed
128.
go back to reference H. Bruehl, O.T. Wolf, V. Sweat, A. Tirsi, S. Richardson, A. Convit, Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 1280, 186–194 (2009)PubMedCentralPubMed H. Bruehl, O.T. Wolf, V. Sweat, A. Tirsi, S. Richardson, A. Convit, Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 1280, 186–194 (2009)PubMedCentralPubMed
129.
go back to reference R.M. Reynolds, M.W. Strachan, J. Labad, A.J. Lee, B.M. Frier, F.G. Fowkes, R. Mitchell, J.R. Seckl, I.J. Deary, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study Investigators, Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33, 714–720 (2010)PubMedCentralPubMed R.M. Reynolds, M.W. Strachan, J. Labad, A.J. Lee, B.M. Frier, F.G. Fowkes, R. Mitchell, J.R. Seckl, I.J. Deary, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study Investigators, Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33, 714–720 (2010)PubMedCentralPubMed
130.
go back to reference T.C. Sandeep, J.L. Yau, A.M. MacLullich, J. Noble, I.J. Deary, B.R. Walker, J.R. Seckl, 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 101, 6734–6739 (2004)PubMedCentralPubMed T.C. Sandeep, J.L. Yau, A.M. MacLullich, J. Noble, I.J. Deary, B.R. Walker, J.R. Seckl, 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 101, 6734–6739 (2004)PubMedCentralPubMed
131.
go back to reference M. Duong, J.I. Cohen, A. Convit, High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine 41, 76–81 (2012)PubMedCentralPubMed M. Duong, J.I. Cohen, A. Convit, High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine 41, 76–81 (2012)PubMedCentralPubMed
132.
go back to reference M. Christ-Crain, B. Kola, F. Lolli, C. Fekete, D. Seboek, G. Wittmann, D. Feltrin, S.C. Igreja, S. Ajodha, J. Harvey-White, G. Kunos, B. Müller, F. Pralong, G. Aubert, G. Arnaldi, G. Giacchetti, M. Boscaro, A.B. Grossman, M. Korbonits, AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 22, 1672–1683 (2008)PubMed M. Christ-Crain, B. Kola, F. Lolli, C. Fekete, D. Seboek, G. Wittmann, D. Feltrin, S.C. Igreja, S. Ajodha, J. Harvey-White, G. Kunos, B. Müller, F. Pralong, G. Aubert, G. Arnaldi, G. Giacchetti, M. Boscaro, A.B. Grossman, M. Korbonits, AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 22, 1672–1683 (2008)PubMed
133.
go back to reference H. Djursing, H.C. Nyholm, C. Hagen, L. Carstensen, L.M. Pedersen, Clinical and hormonal characteristics in women with anovulation and insulin-treated diabetes mellitus. Am. J. Obstet. Gynecol. 143, 876–882 (1982)PubMed H. Djursing, H.C. Nyholm, C. Hagen, L. Carstensen, L.M. Pedersen, Clinical and hormonal characteristics in women with anovulation and insulin-treated diabetes mellitus. Am. J. Obstet. Gynecol. 143, 876–882 (1982)PubMed
134.
go back to reference G. Reimondo, A. Pia, B. Allasino, F. Tassone, S. Bovio, G. Borretta, A. Angeli, M. Terzolo, Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin. Endocrinol. (Oxf) 67, 225–229 (2007) G. Reimondo, A. Pia, B. Allasino, F. Tassone, S. Bovio, G. Borretta, A. Angeli, M. Terzolo, Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin. Endocrinol. (Oxf) 67, 225–229 (2007)
135.
go back to reference B. Catargi, V. Rigalleau, A. Poussin, N. Ronci-Chaix, V. Bex, V. Vergnot, H. Gin, P. Roger, A. Tabarin, Occult Cushing’s syndrome in type-2 diabetes. J. Clin. Endocrinol. Metab. 88, 5808–5813 (2003)PubMed B. Catargi, V. Rigalleau, A. Poussin, N. Ronci-Chaix, V. Bex, V. Vergnot, H. Gin, P. Roger, A. Tabarin, Occult Cushing’s syndrome in type-2 diabetes. J. Clin. Endocrinol. Metab. 88, 5808–5813 (2003)PubMed
136.
go back to reference M. Terzolo, G. Reimondo, I. Chiodini, R. Castello, R. Giordano, E. Ciccarelli, P. Limone, C. Crivellaro, I. Martinelli, M. Montini, O. Disoteo, B. Ambrosi, R. Lanzi, M. Arosio, S. Senni, A. Balestrieri, E. Solaroli, B. Madeo, R. De Giovanni, F. Strollo, R. Battista, A. Scorsone, V.A. Giagulli, D. Collura, A. Scillitani, R. Cozzi, M. Faustini-Fustini, A. Pia, R. Rinaldi, B. Allasino, G. Peraga, F. Tassone, P. Garofalo, E. Papini, G. Borretta, Screening of Cushing’s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J. Clin. Endocrinol. Metab. 97, 3467–3475 (2012)PubMed M. Terzolo, G. Reimondo, I. Chiodini, R. Castello, R. Giordano, E. Ciccarelli, P. Limone, C. Crivellaro, I. Martinelli, M. Montini, O. Disoteo, B. Ambrosi, R. Lanzi, M. Arosio, S. Senni, A. Balestrieri, E. Solaroli, B. Madeo, R. De Giovanni, F. Strollo, R. Battista, A. Scorsone, V.A. Giagulli, D. Collura, A. Scillitani, R. Cozzi, M. Faustini-Fustini, A. Pia, R. Rinaldi, B. Allasino, G. Peraga, F. Tassone, P. Garofalo, E. Papini, G. Borretta, Screening of Cushing’s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J. Clin. Endocrinol. Metab. 97, 3467–3475 (2012)PubMed
137.
go back to reference I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, G. Adda, V. Trischitta, Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case–control study in hospitalized patients. Eur. J. Endocrinol. 153, 837–844 (2005)PubMed I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, G. Adda, V. Trischitta, Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case–control study in hospitalized patients. Eur. J. Endocrinol. 153, 837–844 (2005)PubMed
138.
go back to reference R. Pasquali, S. Cantobelli, F. Casimirri, M. Capelli, L. Bortoluzzi, R. Flamia, A.M. Labate, L. Barbara, The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77, 341–346 (1993)PubMed R. Pasquali, S. Cantobelli, F. Casimirri, M. Capelli, L. Bortoluzzi, R. Flamia, A.M. Labate, L. Barbara, The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77, 341–346 (1993)PubMed
139.
go back to reference R. Rosmond, M.F. Dallman, P. Björntorp, Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 83, 1853–1859 (1998)PubMed R. Rosmond, M.F. Dallman, P. Björntorp, Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 83, 1853–1859 (1998)PubMed
140.
go back to reference E. Torrecilla, G. Fernández-Vázquez, D. Vicent, F. Sánchez-Franco, A. Barabash, L. Cabrerizo, A. Sánchez-Pernaute, A.J. Torres, M.A. Rubio, Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes. Surg. 22, 478–486 (2012)PubMed E. Torrecilla, G. Fernández-Vázquez, D. Vicent, F. Sánchez-Franco, A. Barabash, L. Cabrerizo, A. Sánchez-Pernaute, A.J. Torres, M.A. Rubio, Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes. Surg. 22, 478–486 (2012)PubMed
141.
go back to reference V. Vicennati, R. Pasquali, Abnormalities of the hypothalamic–pituitary–adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. J. Clin. Endocrinol. Metab. 85, 4093–4098 (2000)PubMed V. Vicennati, R. Pasquali, Abnormalities of the hypothalamic–pituitary–adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. J. Clin. Endocrinol. Metab. 85, 4093–4098 (2000)PubMed
142.
go back to reference T. Reinehr, W. Andler, Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm. Res. 62, 107–112 (2004)PubMed T. Reinehr, W. Andler, Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm. Res. 62, 107–112 (2004)PubMed
143.
go back to reference D.J. Wake, E. Rask, D.E. Livingstone, S. Söderberg, T. Olsson, B.R. Walker, Local and systemic impact of transcriptional up-regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88, 3983–3988 (2003)PubMed D.J. Wake, E. Rask, D.E. Livingstone, S. Söderberg, T. Olsson, B.R. Walker, Local and systemic impact of transcriptional up-regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88, 3983–3988 (2003)PubMed
144.
go back to reference C. Wang, G. Jackson, T.H. Jones, A.M. Matsumoto, A. Nehra, M.A. Perelman, R.S. Swerdloff, A. Traish, M. Zitzmann, G. Cunningham, Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34, 1669–1675 (2011)PubMedCentralPubMed C. Wang, G. Jackson, T.H. Jones, A.M. Matsumoto, A. Nehra, M.A. Perelman, R.S. Swerdloff, A. Traish, M. Zitzmann, G. Cunningham, Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34, 1669–1675 (2011)PubMedCentralPubMed
145.
go back to reference S. Wei, M.D. Schmidt, T. Dwyer, R.J. Norman, A.J. Venn, Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring). 17, 1070–1076 (2009)PubMed S. Wei, M.D. Schmidt, T. Dwyer, R.J. Norman, A.J. Venn, Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring). 17, 1070–1076 (2009)PubMed
146.
go back to reference V. Vicennati, L. Ceroni, S. Genghini, L. Patton, U. Pagotto, R. Pasquali, Sex difference in the relationship between the hypothalamic–pituitary–adrenal axis and sex hormones in obesity. Obesity (Silver Spring). 14, 235–243 (2006)PubMed V. Vicennati, L. Ceroni, S. Genghini, L. Patton, U. Pagotto, R. Pasquali, Sex difference in the relationship between the hypothalamic–pituitary–adrenal axis and sex hormones in obesity. Obesity (Silver Spring). 14, 235–243 (2006)PubMed
147.
go back to reference C.K. Buffington, J.R. Givens, A.E. Kitabchi, Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women. Metabolism 43, 584–590 (1994)PubMed C.K. Buffington, J.R. Givens, A.E. Kitabchi, Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women. Metabolism 43, 584–590 (1994)PubMed
148.
go back to reference T. Grimmichová, J. Vrbíková, P. Matucha, K. Vondra, P.P. Veldhuis, M.L. Johnson, Fasting insulin pulsatile secretion in lean women with polycystic ovary syndrome. Physiol. Res. 57(Suppl 1), 91–98 (2008) T. Grimmichová, J. Vrbíková, P. Matucha, K. Vondra, P.P. Veldhuis, M.L. Johnson, Fasting insulin pulsatile secretion in lean women with polycystic ovary syndrome. Physiol. Res. 57(Suppl 1), 91–98 (2008)
149.
go back to reference M. Hollingdal, C.B. Juhl, R. Dall, J. Sturis, J.D. Veldhuis, O. Schmitz, N. Pørksen, Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45, 49–55 (2002)PubMed M. Hollingdal, C.B. Juhl, R. Dall, J. Sturis, J.D. Veldhuis, O. Schmitz, N. Pørksen, Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45, 49–55 (2002)PubMed
150.
go back to reference M. Zarković, J. Cirić, Z. Penezić, B. Trbojević, M. Drezgić, Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome. Gynecol. Endocrinol. 15, 381–388 (2001)PubMed M. Zarković, J. Cirić, Z. Penezić, B. Trbojević, M. Drezgić, Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome. Gynecol. Endocrinol. 15, 381–388 (2001)PubMed
151.
go back to reference R. Pascualy, Sleep apnea and type 2 diabetes. A vicious circle. Diabetes Self. Manag. 24, 29–30 (2007)PubMed R. Pascualy, Sleep apnea and type 2 diabetes. A vicious circle. Diabetes Self. Manag. 24, 29–30 (2007)PubMed
152.
go back to reference G. Copinschi, Metabolic and endocrine effects of sleep deprivation. Essent. Psychopharmacol. 6, 341–347 (2005)PubMed G. Copinschi, Metabolic and endocrine effects of sleep deprivation. Essent. Psychopharmacol. 6, 341–347 (2005)PubMed
153.
go back to reference J.C. Lam, C.S. Yan, A.Y. Lai, S. Tam, D.Y. Fong, B. Lam, M.S. Ip, Determinants of daytime blood pressure in relation to obstructive sleep apnea in men. Lung 187, 291–298 (2009)PubMed J.C. Lam, C.S. Yan, A.Y. Lai, S. Tam, D.Y. Fong, B. Lam, M.S. Ip, Determinants of daytime blood pressure in relation to obstructive sleep apnea in men. Lung 187, 291–298 (2009)PubMed
154.
go back to reference C. Parlapiano, M.C. Borgia, A. Minni, N. Alessandri, I. Basal, M. Saponara, Cortisol circadian rhythm and 24-hour Holter arterial pressure in OSAS patients. Endocr. Res. 31, 371–374 (2005)PubMed C. Parlapiano, M.C. Borgia, A. Minni, N. Alessandri, I. Basal, M. Saponara, Cortisol circadian rhythm and 24-hour Holter arterial pressure in OSAS patients. Endocr. Res. 31, 371–374 (2005)PubMed
155.
go back to reference P.P. Roy-Byrne, T.W. Uhde, R.M. Post, W. Gallucci, G.P. Chrousos, P.W. Gold, The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry 143, 896–899 (1986)PubMed P.P. Roy-Byrne, T.W. Uhde, R.M. Post, W. Gallucci, G.P. Chrousos, P.W. Gold, The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry 143, 896–899 (1986)PubMed
156.
go back to reference D.H. Avery, T.B. Osgood, D.M. Ishiki, L.G. Wilson, M. Kenny, D.L. Dunner, The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am. J. Psychiatry 142, 844–848 (1985)PubMed D.H. Avery, T.B. Osgood, D.M. Ishiki, L.G. Wilson, M. Kenny, D.L. Dunner, The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am. J. Psychiatry 142, 844–848 (1985)PubMed
157.
go back to reference R.G. Kathol, R. Anton, R. Noyes, T. Gehris, Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol. Psychiatry 25, 873–878 (1989)PubMed R.G. Kathol, R. Anton, R. Noyes, T. Gehris, Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol. Psychiatry 25, 873–878 (1989)PubMed
158.
go back to reference R.G. Kathol, R. Noyes Jr, A.L. Lopez, J.H. Reich, Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res. 24, 211–221 (1988)PubMed R.G. Kathol, R. Noyes Jr, A.L. Lopez, J.H. Reich, Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res. 24, 211–221 (1988)PubMed
159.
go back to reference P. Westberg, K. Modigh, P. Lisjö, E. Eriksson, Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol. Psychiatry 30, 247–256 (1991)PubMed P. Westberg, K. Modigh, P. Lisjö, E. Eriksson, Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol. Psychiatry 30, 247–256 (1991)PubMed
160.
go back to reference B. Bandelow, D. Wedekind, V. Sandvoss, A. Broocks, G. Hajak, J. Pauls, H. Peter, E. Rüther, Diurnal variation of cortisol in panic disorder. Psychiatry Res. 95, 245–250 (2000)PubMed B. Bandelow, D. Wedekind, V. Sandvoss, A. Broocks, G. Hajak, J. Pauls, H. Peter, E. Rüther, Diurnal variation of cortisol in panic disorder. Psychiatry Res. 95, 245–250 (2000)PubMed
161.
go back to reference J.L. Abelson, G.C. Curtis, Hypothalamic–pituitary–adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch. Gen. Psychiatry 53, 323–331 (1996)PubMed J.L. Abelson, G.C. Curtis, Hypothalamic–pituitary–adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch. Gen. Psychiatry 53, 323–331 (1996)PubMed
162.
go back to reference National Collaborating Centre for Mental Health (UK) Generalised Anxiety Disorder in Adults.: Management in Primary, Secondary and Community Care. pp 19. London: Royal College of Psychiatrists (2011) National Collaborating Centre for Mental Health (UK) Generalised Anxiety Disorder in Adults.: Management in Primary, Secondary and Community Care. pp 19. London: Royal College of Psychiatrists (2011)
163.
go back to reference E.E. Schweizer, C.M. Swenson, A. Winokur, K. Rickels, G. Maislin, The dexamethasone suppression test in generalised anxiety disorder. Br. J. Psychiatry 149, 320–322 (1986)PubMed E.E. Schweizer, C.M. Swenson, A. Winokur, K. Rickels, G. Maislin, The dexamethasone suppression test in generalised anxiety disorder. Br. J. Psychiatry 149, 320–322 (1986)PubMed
164.
go back to reference R.C. Mantella, M.A. Butters, J.A. Amico, S. Mazumdar, B.L. Rollman, A.E. Begley, C.F. Reynolds, E.J. Lenze, Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 33, 773–781 (2008)PubMedCentralPubMed R.C. Mantella, M.A. Butters, J.A. Amico, S. Mazumdar, B.L. Rollman, A.E. Begley, C.F. Reynolds, E.J. Lenze, Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 33, 773–781 (2008)PubMedCentralPubMed
165.
go back to reference S.A. Vreeburg, F.G. Zitman, J. van Pelt, R.H. Derijk, J.C. Verhagen, R. van Dyck, W.J. Hoogendijk, J.H. Smit, B.W. Penninx, Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72, 340–347 (2010)PubMed S.A. Vreeburg, F.G. Zitman, J. van Pelt, R.H. Derijk, J.C. Verhagen, R. van Dyck, W.J. Hoogendijk, J.H. Smit, B.W. Penninx, Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72, 340–347 (2010)PubMed
167.
go back to reference L. Manenschijn, R.G. van Kruysbergen, F.H. de Jong, J.W. Koper, E.F. van Rossum, Shift work at young age is associated with elevated long-term cortisol levels and body mass index. J. Clin. Endocrinol. Metab. 96, 1862–1865 (2011) L. Manenschijn, R.G. van Kruysbergen, F.H. de Jong, J.W. Koper, E.F. van Rossum, Shift work at young age is associated with elevated long-term cortisol levels and body mass index. J. Clin. Endocrinol. Metab. 96, 1862–1865 (2011)
168.
go back to reference H. Raff, H. Trivedi, Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr. Connect. 19, 23–31 (2012) H. Raff, H. Trivedi, Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr. Connect. 19, 23–31 (2012)
169.
go back to reference K. Carlström, A. Pousette, R. Stege, A. Lindholm, Serum hormone levels in men with end stage renal disease. Scand. J. Urol. Nephrol. 24, 75–78 (1990)PubMed K. Carlström, A. Pousette, R. Stege, A. Lindholm, Serum hormone levels in men with end stage renal disease. Scand. J. Urol. Nephrol. 24, 75–78 (1990)PubMed
170.
go back to reference F. Hammer, N.C. Edwards, B.A. Hughes, R.P. Steeds, C.J. Ferro, J.N. Townend, P.M. Stewart, The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin. Endocrinol. (Oxf) 73, 566–572 (2010) F. Hammer, N.C. Edwards, B.A. Hughes, R.P. Steeds, C.J. Ferro, J.N. Townend, P.M. Stewart, The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin. Endocrinol. (Oxf) 73, 566–572 (2010)
171.
go back to reference M. Walser, S. Hill, Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. Am. J. Kidney Dis. 29, 503–513 (1997)PubMed M. Walser, S. Hill, Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. Am. J. Kidney Dis. 29, 503–513 (1997)PubMed
172.
go back to reference S.H. Shah, L.K. Newby, C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 11, 169–179 (2003)PubMed S.H. Shah, L.K. Newby, C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 11, 169–179 (2003)PubMed
173.
go back to reference M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson, American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42, 1050–1065 (2003)PubMed M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson, American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42, 1050–1065 (2003)PubMed
174.
go back to reference B.J. Carroll, A. Iranmanesh, D.M. Keenan, F. Cassidy, W.H. Wilson, J.D. Veldhuis, Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. Acta Psychiatr. Scand. 125, 478–491 (2012)PubMedCentralPubMed B.J. Carroll, A. Iranmanesh, D.M. Keenan, F. Cassidy, W.H. Wilson, J.D. Veldhuis, Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. Acta Psychiatr. Scand. 125, 478–491 (2012)PubMedCentralPubMed
175.
go back to reference J. Licinio, M.L. Wong, P.W. Gold, The hypothalamic–pituitary–adrenal axis in anorexia nervosa. Psychiatry Res. 62, 75–83 (1996)PubMed J. Licinio, M.L. Wong, P.W. Gold, The hypothalamic–pituitary–adrenal axis in anorexia nervosa. Psychiatry Res. 62, 75–83 (1996)PubMed
176.
go back to reference G.S. Birketvedt, E. Drivenes, I. Agledahl, J. Sundsfjord, R. Olstad, J.R. Florholmen, Bulimia nervosa: a primary defect in the hypothalamic–pituitary–adrenal axis? Appetite 46, 164–167 (2006)PubMed G.S. Birketvedt, E. Drivenes, I. Agledahl, J. Sundsfjord, R. Olstad, J.R. Florholmen, Bulimia nervosa: a primary defect in the hypothalamic–pituitary–adrenal axis? Appetite 46, 164–167 (2006)PubMed
177.
go back to reference T.P. Beresford, D.B. Arciniegas, J. Alfers, L. Clapp, B. Martin, H.F. Beresford, Y. Du, D. Liu, D. Shen, C. Davatzikos, M.L. Laudenslager, Hypercortisolism in alcohol dependence and its relation to hippocampal volume loss. J. Stud. Alcohol 67, 861–867 (2006)PubMed T.P. Beresford, D.B. Arciniegas, J. Alfers, L. Clapp, B. Martin, H.F. Beresford, Y. Du, D. Liu, D. Shen, C. Davatzikos, M.L. Laudenslager, Hypercortisolism in alcohol dependence and its relation to hippocampal volume loss. J. Stud. Alcohol 67, 861–867 (2006)PubMed
178.
go back to reference A. Smals, P. Kloppenborg, Alcohol-induced pseudo-Cushings syndrome. Lancet 1, 1369 (1977)PubMed A. Smals, P. Kloppenborg, Alcohol-induced pseudo-Cushings syndrome. Lancet 1, 1369 (1977)PubMed
179.
go back to reference R.H. Stimson, R. Andrew, N.C. McAvoy, D. Tripathi, P.C. Hayes, B.R. Walker, Increased whole-body and sustained liver cortisol regeneration by 11 beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60, 720–725 (2011)PubMedCentralPubMed R.H. Stimson, R. Andrew, N.C. McAvoy, D. Tripathi, P.C. Hayes, B.R. Walker, Increased whole-body and sustained liver cortisol regeneration by 11 beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60, 720–725 (2011)PubMedCentralPubMed
180.
go back to reference R. Pasquali, V. Vicennati, Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), 47–49 (2000) R. Pasquali, V. Vicennati, Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), 47–49 (2000)
181.
go back to reference R. Pasquali, V. Vicennati, A. Gambineri, Adrenal and gonadal function in obesity. J. Endocrinol. Invest. 25, 893–898 (2002)PubMed R. Pasquali, V. Vicennati, A. Gambineri, Adrenal and gonadal function in obesity. J. Endocrinol. Invest. 25, 893–898 (2002)PubMed
182.
go back to reference B.R. Walker, R. Andrew, Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann. N. Y. Acad. Sci. 1083, 165–184 (2006)PubMed B.R. Walker, R. Andrew, Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann. N. Y. Acad. Sci. 1083, 165–184 (2006)PubMed
183.
go back to reference R. Desbriere, V. Vuaroqueaux, V. Achard, S. Boullu-Ciocca, M. Labuhn, A. Dutour, M. Grino, 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14, 794–798 (2006) R. Desbriere, V. Vuaroqueaux, V. Achard, S. Boullu-Ciocca, M. Labuhn, A. Dutour, M. Grino, 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14, 794–798 (2006)
184.
go back to reference T. Tsilchorozidou, J.W. Honour, G.S. Conway, Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5 alpha-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 88, 5907–5913 (2003)PubMed T. Tsilchorozidou, J.W. Honour, G.S. Conway, Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5 alpha-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 88, 5907–5913 (2003)PubMed
185.
go back to reference F. Roelfsema, P. Kok, A.M. Pereira, H. Pijl, Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 3318–3324 (2010)PubMed F. Roelfsema, P. Kok, A.M. Pereira, H. Pijl, Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 3318–3324 (2010)PubMed
186.
go back to reference A. Gambineri, G. Forlani, A. Munarini, F. Tomassoni, G.E. Cognigni, W. Ciampaglia, U. Pagotto, B.R. Walker, R. Pasquali, Increased clearance of cortisol by 5 beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J. Endocrinol. Invest. 32, 210–218 (2009)PubMed A. Gambineri, G. Forlani, A. Munarini, F. Tomassoni, G.E. Cognigni, W. Ciampaglia, U. Pagotto, B.R. Walker, R. Pasquali, Increased clearance of cortisol by 5 beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J. Endocrinol. Invest. 32, 210–218 (2009)PubMed
187.
go back to reference L.M. Tomfohr, K.M. Edwards, J.E. Dimsdale, Is obstructive sleep apnea associated with cortisol levels? A systematic review of the research evidence. Sleep Med. Rev. 16, 243–249 (2012)PubMedCentralPubMed L.M. Tomfohr, K.M. Edwards, J.E. Dimsdale, Is obstructive sleep apnea associated with cortisol levels? A systematic review of the research evidence. Sleep Med. Rev. 16, 243–249 (2012)PubMedCentralPubMed
188.
go back to reference T.M. Buckley, A.F. Schatzberg, On the interactions of the hypothalamic–pituitary–adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 90, 3106–3114 (2005)PubMed T.M. Buckley, A.F. Schatzberg, On the interactions of the hypothalamic–pituitary–adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 90, 3106–3114 (2005)PubMed
189.
go back to reference M. Clodi, M. Riedl, S. Schmaldienst, A. Vychytil, H. Kotzmann, A. Kaider, C. Bieglmayer, G. Mayer, W. Waldhäusl, A. Luger, Adrenal function in patients with chronic renal failure. Am. J. Kidney Dis. 32, 52–55 (1998)PubMed M. Clodi, M. Riedl, S. Schmaldienst, A. Vychytil, H. Kotzmann, A. Kaider, C. Bieglmayer, G. Mayer, W. Waldhäusl, A. Luger, Adrenal function in patients with chronic renal failure. Am. J. Kidney Dis. 32, 52–55 (1998)PubMed
Metadata
Title
Harmful effects of functional hypercortisolism: a working hypothesis
Authors
Giacomo Tirabassi
Marco Boscaro
Giorgio Arnaldi
Publication date
01-08-2014
Publisher
Springer US
Published in
Endocrine / Issue 3/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0112-y

Other articles of this Issue 3/2014

Endocrine 3/2014 Go to the issue